Recombinant protein vaccine
ATC code: J07BC01 (Hepatitis B vaccine)
Contains hepatitis B surface antigen (HBsAg) produced recombinantly in yeast. Adjuvant – aluminum salts. Three-dose schedule (0-1-6 months) achieves protective titers (anti-HBs ≥10 mIU/mL) in 95% of adults, 50-70% in immunocompromised. Lifelong immunity after full series.
First line
Hepatitis B during breastfeeding. Per CDC ACIP 2024 and SEGO 2023, fully compatible. If unvaccinated and in a risk group (healthcare worker, HBV+ partner, HIV+), vaccinate without interrupting breastfeeding.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Use in pregnancy when indicated. Safe.
Fully compatible. Hale L1.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Hepatitis B vaccine, recombinant is evaluated for the following indications with varying evidence strength: Vaccination during breastfeeding (evidence tier A). See the full indication matrix with dosing and citations above on this page.
Common side effects of Hepatitis B vaccine, recombinant (≥ 1 in 100): Injection-site pain (10-30%), Fatigue, Headache. See the Safety section for uncommon and serious reactions.
FDA category C. Use in pregnancy when indicated. Safe.
Fully compatible. Hale L1.
Hepatitis B vaccine, recombinant is contraindicated in: Anaphylaxis to previous dose or components (yeast); Acute febrile illness (defer). Full list in the Safety section.